These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

102 related items for PubMed ID: 6201713

  • 1. [Specific active immunotherapy of murine methylcholanthrene-induced sarcoma using a partially purified soluble tumor specific transplantation antigens].
    Tanaka T, Yamagishi H, Inaba S, Kobayashi M, Kurioka H, Naito K, Hashimoto I.
    Nihon Geka Gakkai Zasshi; 1983 Apr; 84(4):282-94. PubMed ID: 6201713
    [Abstract] [Full Text] [Related]

  • 2. Immunotherapy of a carcinogen-induced murine sarcoma with soluble tumor-specific transplantation antigens.
    Kahan BD, Tanaka T, Pellis NR.
    J Natl Cancer Inst; 1980 Nov; 65(5):1001-4. PubMed ID: 6159495
    [Abstract] [Full Text] [Related]

  • 3. Immunotherapeutic effects of partially purified tumor-specific transplantation antigens on pulmonary metastases of a 3-methylcholanthrene-induced sarcoma in mice: a preliminary report.
    Tanaka T, Pellis NR, Kahan BD.
    J Natl Cancer Inst; 1982 Nov; 69(5):1121-6. PubMed ID: 6957656
    [Abstract] [Full Text] [Related]

  • 4. [The immunotherapeutic effect of partially purified tumor specific transplantation antigen against pulmonary metastasis].
    Inaba S, Tanaka T, Yamagishi H, Kobayashi M, Tsuchiya K, Oka T.
    Nihon Gan Chiryo Gakkai Shi; 1984 Dec 20; 19(10):2273-8. PubMed ID: 6533208
    [No Abstract] [Full Text] [Related]

  • 5. Retardation of postsurgical metastases with the use of extracted tumor-specific transplantation antigens and cyclophosphamide.
    Nomi S, Pellis NR, Kahan BD.
    J Natl Cancer Inst; 1984 Oct 20; 73(4):943-50. PubMed ID: 6237215
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide.
    Naito K, Pellis NR, Kahan BD.
    Cancer Res; 1988 Jan 01; 48(1):101-8. PubMed ID: 3257158
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Intrasplenic administration of interleukin-2 to potentiate specific chemoimmunotherapy in tumor-bearing mice.
    Nomi S, Naito K, Kahan BD, Pellis NR.
    Cancer Res; 1986 Nov 01; 46(11):5606-10. PubMed ID: 2875791
    [Abstract] [Full Text] [Related]

  • 11. Biological and biochemical properties of Nonidet P40-solubilized and partially purified tumor-specific antigens of the transplantation type from plasma membranes of a methylcholanthrene-induced sarcoma.
    Natori T, Law LW, Appella E.
    Cancer Res; 1977 Sep 01; 37(9):3406-13. PubMed ID: 69494
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Subcutaneous injection of spleen cells from mice bearing large methylcholanthrene-induced sarcoma enhances subcutaneous tumors and artificial pulmonary metastases].
    Tsuchiya K, Yamagishi H, Hamada H, Komichi H, Oka T, Tanaka T, Inaba S.
    Nihon Geka Gakkai Zasshi; 1987 Jul 01; 88(7):826-31. PubMed ID: 2444868
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Establishment and immunologic characterization of 3-methylcholanthrene-induced sarcoma cell lines metastasizing widely in mice and exhibiting distinct and selective propensities for the mode of metastasis.
    Kodama Y, Seyama T, Kamiya K, Yokoro K.
    J Natl Cancer Inst; 1982 Sep 01; 69(3):595-605. PubMed ID: 7050499
    [Abstract] [Full Text] [Related]

  • 16. Specific tumor immunity induced with soluble materials: restricted range of antigen dose and of challenge tumor load for immunoprotection.
    Pellis NR, Kahan BD.
    J Immunol; 1975 Dec 01; 115(6):1717-22. PubMed ID: 52676
    [Abstract] [Full Text] [Related]

  • 17. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ, Mulé JJ, Rosenberg SA.
    Cancer Res; 1986 Oct 01; 46(10):4973-8. PubMed ID: 3489517
    [Abstract] [Full Text] [Related]

  • 18. Tumor-specific and allospecific immunogenicity of soluble extracts from chemically induced murine sarcomas.
    Pellis NR, Tom BH, Kahan BD.
    J Immunol; 1974 Aug 01; 113(2):708-11. PubMed ID: 4136043
    [No Abstract] [Full Text] [Related]

  • 19. Immunobiological properties of 1-butanol-extracted cell surface antigens.
    LeGrue SJ, Allison JP, Macek CM, Pellis NR, Kahan BD.
    Cancer Res; 1981 Oct 01; 41(10):3956-60. PubMed ID: 7026027
    [Abstract] [Full Text] [Related]

  • 20. Immunotherapeutic effects of tumor-specific transplantation antigens released by 1-butanol.
    Kahan BD, Pellis NR, LeGrue SJ, Tanaka T.
    Cancer; 1982 Mar 15; 49(6):1168-73. PubMed ID: 7059942
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.